HealthcareServices

Polymyalgia Rheumatica Market Future Outlook 2026: Key Drivers and Growth Potential

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the polymyalgia rheumatica market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Polymyalgia Rheumatica Market in 2030?

The market for polymyalgia rheumatica has shown robust expansion over the past few years. Projections indicate it will expand from $1.36 billion in 2025 to reach $1.44 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by factors such as a rising elderly demographic, enhanced clinical understanding of inflammatory conditions, the widespread adoption of corticosteroids as the initial treatment, increasing diagnostic rates among older patients, and the provision of rheumatology care within hospitals.

The polymyalgia rheumatica market size is projected to observe significant expansion in the coming years. It is forecast to grow to $1.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period is largely due to the increasing development of steroid-sparing therapies, escalating research into inflammatory biomarkers, the rising adoption of biologics and targeted drugs, expanding access to specialized medical care, and a growing focus on reducing long-term treatment side effects. Prominent trends expected in this period include the increased uptake of biologic therapies, a heightened focus on early and accurate diagnosis, the growing implementation of long-term corticosteroid management, the expansion of personalized treatment approaches, and enhanced monitoring of disease progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What Drivers Are Influencing Production Trends In The Polymyalgia Rheumatica Market?

The increasing demand for personalized medicine is anticipated to propel the expansion of the polymyalgia rheumatica market moving forward. Personalized medicine refers to medical care specifically adapted to an individual’s genetic profile, lifestyle, and unique health conditions to achieve more effective results. The impetus behind the need for personalized medicine stems from breakthroughs in genetic research, rising patient desires for customized therapies, and enhancements in diagnostic technologies. Genetic research has provided a profound understanding of distinct genetic variations, enabling the creation of more tailored treatments aimed at specific genetic markers. This approach helps in selecting drugs most likely to be effective based on the patient’s characteristics, thereby leading to a more efficient and secure treatment strategy. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, which was an increase from six in 2022. Consequently, the advent of personalized medicine is fueling the growth of the polymyalgia rheumatica market.

Which Segments Are Gaining Traction In The Polymyalgia Rheumatica Market?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Elderly Or Aging Population

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Which Trends Are Shaping Activity Within The Polymyalgia Rheumatica Market?

Leading firms within the polymyalgia rheumatica market are prioritizing the creation of advanced medications, including interleukin-6 (IL-6) receptor blockers, to offer more precise and potent therapeutic alternatives. These interleukin-6 (IL-6) receptor blockers function as biological agents, working to suppress IL-6, a significant pro-inflammatory cytokine implicated in autoimmune conditions. Their mechanism of action, by inhibiting IL-6, leads to a reduction in inflammation and an alleviation of symptoms, thereby improving the quality of life for individuals suffering from PMR. As an illustration, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology firm, together with Sanofi, a France-based healthcare enterprise, disclosed that the Food and Drug Administration (FDA) had granted approval for Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adults who had not adequately responded to corticosteroids or were unable to gradually discontinue their use. Kevzara, notably the inaugural and sole biologic medication sanctioned for this ailment, operates by preventing IL-6-mediated signaling pathways. This approval stemmed from a clinical investigation demonstrating that 28.3% of patients receiving sarilumab attained sustained remission by week 52, in contrast to 10.3% of those on placebo. Kevzara is administered through subcutaneous injection bi-weekly and has also secured approval for the management of moderately to severely active rheumatoid arthritis. Currently, Sanofi’s stock (SNY) trades at $54.13 on the NASDAQ.

Who Are The Major Companies Operating In The Polymyalgia Rheumatica Market?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Horizon Therapeutics plc, Sparrow Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Amgen Inc., Boehringer Ingelheim, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2025. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Polymyalgia Rheumatica Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2026, By The Business Research Company

Sciatica Market Report 2026

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Fibromyalgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Esophageal Dysphagia Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795